Sutro Biopharma (STRO) Stock in Focus

Shares of Sutro Biopharma moved -5.2% Friday, and are now trading at a price of $7.47. In contrast, the S&P 500 index saw a -0.7% change and the Dow Industrial Average posted a -0.6% performance. Today's trading volume is 241,115 compared to the stock's average volume of 384,146.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. Based in South San Francisco, United States the company has 259 full time employees and a market cap of $429,341,984. The company is now trading -65.06% away from its average analyst target price of $21.38 per share. The 8 analysts following the stock have set target prices ranging from $15 to $33, and on average give Sutro Biopharma a rating of buy.

Over the last year, STRO shares have gone down by -49.9%, which represents a difference of -34.2% when compared to the S&P 500. The stock's 52 week high is $16.6 per share and its 52 week low is $3.33. With its gross margins declining an average -21.8% over the last four years, Sutro Biopharma may not have a strong enough business to reverse this trend.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.